NCT06505928View on ClinicalTrials.gov

A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

December 11, 2025

Study Completion Date

December 1, 2029

Conditions
Hepatitis D
Interventions
DRUG

hepalatide

hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks

Trial Locations (2)

13370

RECRUITING

National cancer canter of Monglia, Ulaanbaatar

Unknown

RECRUITING

National Center for Communicable Diseases, Ulaanbaatar

All Listed Sponsors
lead

Shanghai HEP Pharmaceutical Co., Ltd.

INDUSTRY